STOK: stoketherapeutics.com Net earnings per share for the last 12 months
Stoke Therapeutics (STOK) is fighting for leadership in the RNA therapy segment, facing intense pressure from industry behemoths. Business resilience relies on the success of epilepsy drug trials and strict liquidity control. Diversification into ophthalmology reduces regulatory risks. The current trailing twelve-month earnings per share illustrates profitability, where -3.79 describes the current status of the metric.
%20Earnings%20per%20share%20for%20the%20last%20four%20quarters&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_STOK_-_Stoke-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Stoke Corp - STOK Net earnings per share (EPS TTM) (period 07/04/2022 - 11/14/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns for Stoke (STOK)
- share price and expert price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
Debt to Equity Stoke Therapeutics|STOK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Stoke Corp|STOK - Company Aggregate Debts|Debt to Book Capitalization Ratio Stoke Therapeutics Inc|STOK - Long-Term Liabilities|Company Short-Term Debts Stoke Therapeutics|Quick Liquidity Indicator stoketherapeutics.com
- net income and valuation multiples indicators:
STOK - Net Profit|Future Profit Stoke Therapeutics|STOK - Market Price to Net Income Ratio|Forward P/E Multiple Stoke Corp|STOK - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Stoke Corp|STOK - Operating profit before deduction of amortization|Earnings per share for the last twelve months Stoke Therapeutics|STOK - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months stoketherapeutics.com|STOK - Expected net earnings per share growth this year|Expected earnings per share growth for next year Stoke Therapeutics
- issuer revenue and sales details:
Analysis of all company metrics:STOK - Stoke Therapeutics
The reliability of oligonucleotide supply chains for Stoke Therapeutics (STOK) directly impacts operational efficiency, which is reflected in the trailing 12-month net income per share on the GURU.Markets platform. This indicator measures the portion of profit attributable to a single security over a rolling year, allowing investors to assess the real return on capital relative to the WACC to determine the investment premium.
Key competitors
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TXG (10x Genomics, Inc.)|NTLA: Net earnings per share (EPS TTM)|BioLife Corp (BLFS) - Net earnings per share (EPS TTM)|WVE (wavelifesciences.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Maze Therapeutics Inc|Net earnings per share (EPS TTM) SION|PRME - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TSHA (Taysha Corp)|Earnings per share for the trailing year QURE|MeiraGTx Holdings - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year REGENXBIO Corp (RGNX)|solidbio.com (SLDB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months OCGN|PACB (PacBio Corp) - Net earnings per share (EPS TTM)|BNTC: Earnings per share for the trailing year|Earnings per share for the last twelve months Design Corp (DSGN)|Net earnings per share for the last 12 months Rocket Pharmaceuticals Inc RCKT|FDMT: Net earnings per one share for the last twelve months|LXEO: Earnings per share for the last 12 months|Korro Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Editas Medicine|Silence Therapeutics (SLN) - Earnings per share for the last twelve months|PRQR (ProQR Therapeutics N.V.) - Earnings per share for the last twelve months|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months sangamo.com (SGMO)|Net earnings per share (EPS TTM) NAUT|Net earnings per share (EPS TTM) Metagenomi (MGX)|Earnings per share for the last twelve months Precision BioSciences DTIL|Net earnings per share (EPS TTM) Generation Bio Corp GBIO|Boundless Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Exicure Inc.|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
